Dig Liver Dis: ERAS方案对克罗恩病手术患者术后恢复疗效的回顾性研究

2020-04-04 MedSci原创 MedSci原创

加速康复外科理念(ERAS)为大肠癌患者的术后恢复提供了许多好处。然而,其在克罗恩病(CD)患者中的应用受到质疑,因此,本项研究旨在对其进行相关研究,验证CD患者的ERAS方案的疗效。

背景:加速康复外科理念(ERAS)为大肠癌患者的术后恢复提供了许多好处。然而,其在克罗恩病(CD)患者中的应用受到质疑,因此,本项研究旨在对其进行相关研究,验证CD患者的ERAS方案的疗效。

方法:研究人员回顾性分析了2007年至2018年接受原发性或复发性CD的回盲切除术的患者的临床资料,并将其倾向性匹配分为两个相等的组(ERAS与护理标准)。对人口统计学特征,住院时间,肠功能,口服摄入量和围手术期发病率进行了分析。

结果:研究人员从299名患者中选择了94名患者进行分析。在年龄,性别,美国麻醉医师学会评分,体重指数,既往手术和治疗,手术时间和腹腔镜检查方面均未观察到显着差异。ERAS组和非ERAS组的中位住院时间分别为6天和8天(p<0.001)。在ERAS组和非ERAS组中,首次排便和固体口服的术后中位数分别为第1天和第2天(p <0.001),以及第2天和第4.5 (p < 0.001)。

结论:ERAS实施显示,对于原发性或复发性CD进行了腹腔镜或开放性回肠胆囊切除术的患者,其住院时间缩短,肠功能恢复更快,口服固体摄入更早。

原始出处:Michela Mineccia. Et al. A retrospective study on efficacy of the ERAS protocol in patients undergoing surgery for Crohn disease: A propensity score analysis. Dig Liver Dis.2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2013268, encodeId=6c8c20132687f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Apr 24 00:21:39 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739008, encodeId=92ee1e3900865, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Sep 18 01:21:39 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585700, encodeId=62ab1585e00f7, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Mon Apr 06 12:21:39 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032460, encodeId=6f1a103246044, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Apr 05 00:21:39 CST 2020, time=2020-04-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2013268, encodeId=6c8c20132687f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Apr 24 00:21:39 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739008, encodeId=92ee1e3900865, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Sep 18 01:21:39 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585700, encodeId=62ab1585e00f7, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Mon Apr 06 12:21:39 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032460, encodeId=6f1a103246044, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Apr 05 00:21:39 CST 2020, time=2020-04-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2013268, encodeId=6c8c20132687f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Apr 24 00:21:39 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739008, encodeId=92ee1e3900865, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Sep 18 01:21:39 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585700, encodeId=62ab1585e00f7, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Mon Apr 06 12:21:39 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032460, encodeId=6f1a103246044, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Apr 05 00:21:39 CST 2020, time=2020-04-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2013268, encodeId=6c8c20132687f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Apr 24 00:21:39 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739008, encodeId=92ee1e3900865, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Sep 18 01:21:39 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585700, encodeId=62ab1585e00f7, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Mon Apr 06 12:21:39 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032460, encodeId=6f1a103246044, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Apr 05 00:21:39 CST 2020, time=2020-04-05, status=1, ipAttribution=)]
    2020-04-05 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

JCC:MicroRNA23a在克罗恩病中的过度表达增加了抗TNF的敏感性并保护了上皮屏障

粘膜愈合在克罗恩病治疗中很重要。克罗恩病中肠上皮稳态失调,通透性增加,炎症和腹泻增加是显着的临床表现。MicroRNA是调节基因表达并在炎症性肠病中显示变化的小型非编码RNA。

JCC:口疮性结肠炎对克罗恩病疾病结局的影响

克罗恩病[CD]中肠病变的自然病程尚未完全了解。尽管在诊断时病变的程度通常决定了疾病的程度,但在诊断时见到的某些病变,特别是口疮[AUs]样溃疡,可在随访前消退。

AP&T:维多珠单抗治疗肛周克罗恩病的疗效分析

具有肛周病变和抗TNF治疗失败的克罗恩病患者的治疗极具治疗挑战性。本项研究旨在评估维多珠单抗在肛周克罗恩病中的有效性。

JCC:克罗恩病小肠切除术后切缘炎症对术后早期内镜复发的影响

目前,人们对于克罗恩病[CD]术后早期内镜复发的发病机制和危险因素尚不清楚。因此,本研究旨在确定回肠切除术后切除边缘的组织学炎症是否影响CD内镜复发。

Clinical Trans Gastroenterology:C反应蛋白的正常化可预测克罗恩病患者粘膜愈合

克罗恩病(CD)的治疗目标已从临床和生物学缓解发展为粘膜愈合(MH)和深层缓解(DR)。MH定义为溃疡消失,而DR定义为临床缓解和MH的组合。

武田的维多珠单抗在国内获批,用于治疗中度至重度活动性溃疡性结肠炎和克罗恩病

维多珠单抗是一种人源化单克隆抗体,设计用于特异性拮抗α4β7整联蛋白,从而抑制α4β7整联蛋白与肠粘膜地址素细胞粘附分子1(MAdCAM-1)的结合。